Clinical Trial Update: Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) [Phase 1]

View source ↗

Summary

Phase 1 trial of Auregen's AUR-201 subcutaneous implant for unilateral microtia in Australia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microtia

Drugs mentioned

• AUR-201

Snippet

Sponsor: Auregen Biotherapeutics, SA | Conditions: Microtia | Phase 1 | Status: TERMINATED